2126: Neuroblastoma Post-Infusion

The Neuroblastoma Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures neuroblastoma (NEU) post-HCT data for the reporting period.

This form must be completed for all recipients whose primary disease, as reported on the Pre-TED Disease Classification (2402) Form, is Neuroblastoma (NEU) under Solid tumors. The Post-HCT Neuroblastoma (2126) Form must be completed in conjunction with each Post-HCT Follow-up (2100) Form. This form is designed to capture specific data occurring within the timeframe of each reporting period (i.e., between day 0 and day 100; between day 100 and the six-month date of contact for six-month follow-up; and between the date of contact for the six-month follow-up and the date of contact for the one-year follow-up, etc

*MIBG Therapy and Additional Infusion of Cells
MIBG therapy has been used to deliver targeted radiation to patients with neuroblastoma. This therapy destroys tumors while sparing normal, healthy tissue. MIBG therapy is currently may be used to treat newly diagnosed, used to treat relapsed or refractory neuroblastoma and is being studied as treatment for newly diagnosed high risk patients.
Treatment for high-risk neuroblastoma includes the following:
Induction therapy: Chemotherapy, stem cell collection, surgical resection of primary tumor
Consolidation therapy: High-dose chemotherapy followed by Autologous HCT, radiation therapy
Maintenance therapy: Immunotherapy, Cis-Retinoic acid
Clinical trials have randomized newly diagnosed high risk neuroblastoma patients with MIBG-avid disease to either standard induction therapy or standard induction therapy with the addition of I-131 MIBG. Since the most common side effect of MIBG therapy is low blood counts, the patient’s hematopoietic progenitor stem cells (HPCs or CD34+ cells) are collected and stored prior to the first treatment with MIBG. These HPCs are then available for HCT or as a “rescue” following MIBG therapy.
Effective November 2020, if a neuroblastoma recipient undergoing induction therapy with MIBG therapy receives an infusion of HPCs / CD34+ cells as a “rescue” due to low blood counts, centers no longer need to report this as an HCT.

Links to Sections of Form
Q1 – 159: Disease Assessments at Time of Best Response to HSCT

Manual Updates
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please reference the retired manual section on the Retired Forms Manuals webpage.

Date	Manual Section	Add/ Remove/Modify	Description
1/25/2021	2126: Neuroblastoma Post-Infusion	Add	Version 1 of the Neuroblastoma Post-Infusion section of the Forms Instructions Manual released. Version 1 corresponds to revision 2 of the Form 2126.

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.